Document:

Exhibit
10.21

 

NEITHER
THIS WARRANT NOR ANY OF THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933 OR UNDER THE SECURITIES LAWS OF ANY OTHER JURISDICTION. BY ACQUIRING THIS WARRANT, HOLDER AGREES TO NOT SELL OR OTHERWISE
DISPOSE OF THIS WARRANT OR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT WITHOUT REGISTRATION OR THE APPLICABILITY OF
AN EXEMPTION FROM REGISTRATION UNDER THE AFORESAID ACTS, AND THE RULES AND REGULATIONS THEREUNDER.

 

WARRANT
TO PURCHASE COMMON STOCK

 

Number
of Shares of Common Stock: 50,000 

Date
of Issuance: January 15, 2016 (“Issuance Date”)

 

THIS
CERTIFIES That,
for value received, Merriman Capital, Inc., a California Corporation (including any permitted and registered assigns, the "Holder"),
is entitled to purchase from Creative Realities, Inc., a Minnesota corporation (the "Company"), up to 50,000
shares of Common Stock of the Company (the "Warrant Shares") at the Exercise Price hereunder then in effect.
This Warrant to Purchase Common Stock (this "Warrant") is issued by the Company in in lieu of additional extensions
to past due payments due to Holder, and a modified payment plan related to current payments due to Holder. For purposes of this
Warrant, the term "Exercise Price" shall mean $0.28 per share, subject to adjustment as provided herein, and
the term "Exercise Period" shall mean the period commencing on the Issuance Date and ending on 5:00 p.m. New
York time on the five-year anniversary of the date of this Warrant.

 

1.       EXERCISE
OF WARRANT.

 

(a)      Mechanics
of Exercise. Subject to the terms and conditions hereof, including butnot limited to the provisions of Section 1(c) below,
the rights represented by this Warrant may be exercised in whole or in part at any time or times during the Exercise Period by
delivery of a written notice, in the form attached hereto as Exhibit A (the “Exercise Notice”), of the
Holder’s election to exercise this Warrant. The Holder shall not be required to deliver the original Warrant in order to
effect an exercise hereunder. Execution and delivery of the Exercise Notice with respect to less than all of the Warrant Shares
shall have the same effect as cancellation of the original Warrant and issuance of a new Warrant evidencing the right to purchase
the remaining number of Warrant Shares. On or before the third Trading Day (the “Warrant Share Delivery Date”)
following the date on which the Company shall have received the Exercise Notice, and upon receipt by the Company of (i) payment
to the Company of an amount equal to the applicable Exercise Price multiplied by the number of Warrant Shares as to which this
Warrant is being exercised (the “Aggregate Exercise Price” and together with the Exercise Notice, the “Exercise
Delivery Documents”) in cash or by wire transfer of immediately available funds or (ii) notification from the Holder
that this Warrant is being exercised pursuant to a Cashless Exercise, as defined below, the Company shall issue and dispatch by
overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company’s share register
in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to
such exercise (or work with the Holder to initiate an electronic delivery of Common Stock through the DWAC system of the Depository
Trust Company, if requested). Upon delivery of the Exercise Delivery Documents, the Holder shall be deemed for all corporate purposes
to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective
of the date of delivery of the certificates evidencing such Warrant Shares. If this Warrant is submitted in connection with any
exercise pursuant to Section 1(c) and the number of Warrant Shares represented by this Warrant submitted for exercise is greater
than the number of Warrant Shares being acquired upon an exercise, then the Company shall as soon as practicable, and in no event
later than three business days after any exercise and at its own expense, issue a new Warrant representing the right to purchase
the number of Warrant Shares purchasable immediately prior to such exercise under this Warrant, less the number of Warrant Shares
with respect to which this Warrant is exercised.

 

     

     

    

 

(b)      No
Fractional Shares. No fractional shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment
pursuant hereto. All Warrant Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes
of determining whether the exercise would result in the issuance of any fractional share. If, after aggregation, the exercise
would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay the Holder
otherwise entitled to such fraction a sum in cash equal to the product resulting from multiplying the then current fair market
value of a Warrant Share by such fraction.

 

(c)      Cashless
Exercise. The Holder may, in its sole discretion, exercise this Warrant in whole or in part and, in lieu of making the cash
payment otherwise contemplated to be made to the Company upon such exercise in payment of the Aggregate Exercise Price, elect
instead to receive upon such exercise the “Net Number” of shares of Common Stock determined according to the
following formula (a “Cashless Exercise”):

 

Net
Number = (A x B) - (A x C)

B

 

For
purposes of the foregoing formula:

 

	 	A	=	the total number of shares
    with respect to which this Warrant is then being exercised.

 

	 	B	=	the Weighted Average Price
    of the shares of Common Stock for the five consecutive Trading Days ending on the date immediately preceding the date of the
    Exercise Notice.

 

	 	C	=	the Exercise
    Price then in effect for the applicable Warrant Shares at the time of such exercise.

 

(d)      Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares. In addition to any other rights available to the Holder, if the Company
fails to deliver (or cause its transfer agent to deliver) to the Holder the Warrant Shares pursuant to an exercise on or before
the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open-market transaction
or otherwise), or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of
a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price
(including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying
(1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue,
times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored
(in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would
have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder
purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice
indicating the amount payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount
of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law
or in equity, including without limitation a decree of specific performance or other injunctive relief with respect to the Company’s
failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

    2

     

    

 

(e)      Beneficial
Ownership Restrictions. Notwithstanding anything to the contrary in this Warrant, the Company shall not effect any exercise
of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, to the extent that, after giving
effect to the exercise set forth on the applicable Exercise Notice, such Holder (together with such Holder’s “affiliates,”
as such term is defined in Rule 405 under the Securities Act of 1933, and any Persons acting as a group together with such Holder
or any of such Holder’s affiliates) would beneficially own in excess of the Beneficial Ownership Limitation, as defined
below. For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by such Holder and its
affiliates shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such
determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon (i) conversion of
the remaining unexercised portion of this Warrant beneficially owned by such Holder or any of its affiliates and (ii) exercise
or conversion of the unexercised or unconverted portion of any other securities of the Company that are subject to a limitation
on conversion or exercise analogous to the limitation contained herein beneficially owned by such Holder or any of its affiliates.
Except as set forth in the preceding sentence, for purposes of this Section, beneficial ownership shall be calculated in accordance
with Section 13(d) of the Securities Exchange Act of 1934 (the “Exchange  Act”). To ensure compliance with
this restriction, each Holder will be deemed to represent to the Company each time it delivers an Exercise Notice that such Exercise
Notice has not violated the restrictions set forth in this Section 1(e) and the Company shall have no obligation to verify or
confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be
determined in accordance with Section 13(d) of the Exchange Act.

 

For
purposes of this Section 1(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number
of outstanding shares of Common Stock as stated in the most recent of the following: (i) the Company’s most recent periodic
or annual report filed with the U.S. Securities and Exchange Commission, as the case may be, (ii) a more recent public announcement
by the Company, or (iii) a more recent written notice by the Company or its transfer agent setting forth the number of shares
of Common Stock outstanding. Upon the written or oral request of a Holder, the Company
shall within two Trading Days confirm to such Holder the number of shares of Common Stock then outstanding. In any case, the number
of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the
Company, including this Warrant, by such Holder or its affiliates. The “Beneficial Ownership Limitation” shall
be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of
Common Stock issuable upon exercise of this Warrant. Upon no fewer than 61 days’ prior notice to the Company, a Holder may
increase or decrease the Beneficial Ownership Limitation provisions of this paragraph, provided that the Beneficial Ownership
Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to
the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this paragraph shall
continue to apply. Any such increase or decrease will not be effective until the 61st day after such notice is delivered to the
Company and shall only apply to such Holder and no other Holder. The limitations contained in this paragraph shall apply to a
successor Holder of this Warrant.

 

    3

     

    

 

2.        ADJUSTMENTS.
The Exercise Price and the number of Warrant Shares shall be adjusted from time to time as follows:

 

(a)     Subdivision
or Combination of Common Stock. If the Company at any time on or after the date of the Note subdivides (by any stock split,
stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock into a greater number
of shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced and the number of
Warrant Shares will be proportionately increased. If the Company at any time on or after the date of the Note combines (by combination,
reverse stock split or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares,
the Exercise Price in effect immediately prior to such combination will be proportionately increased and the number of Warrant
Shares will be proportionately decreased. Any adjustment under this Section 2(a) shall become effective at the close of business
on the date the subdivision or combination becomes effective.

 

(b)    Distribution
of Assets. If the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its
assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including without limitation any distribution
of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement
or other similar transaction) (a “Distribution”), at any time after the issuance of this Warrant, then, in
each such case:

 

(i)     any
Exercise Price in effect immediately prior to the close of business on the record date fixed for the determination of holders
of shares of Common Stock entitled to receive the Distribution shall be reduced, effective as of the close of business on such
record date, to a price determined by multiplying such Exercise Price by a fraction of which (i) the numerator shall be the Closing
Sale Price of the shares of Common Stock on the Trading Day immediately preceding such record date minus the value of the Distribution
(as determined in good faith by the Company’s Board of Directors) applicable to one share of Common Stock, and (ii) the
denominator shall be the Closing Sale Price of the shares of Common Stock on the Trading Day immediately preceding such record
date; and

 

    4

     

    

 

(ii)     the
number of Warrant Shares shall be increased to a number of shares equal to the number of shares of Common Stock obtainable immediately
prior to the close of business on the record date fixed for the determination of holders of shares of Common Stock entitled to
receive the Distribution multiplied by the reciprocal of the fraction set forth in the immediately preceding clause (i); provided,
however, that in the event that the Distribution is of shares of common stock of a company (other than the Company) whose common
stock is traded on a national securities exchange or a national automated quotation system (“Other Shares of Common Stock”),
then the Holder may elect to receive a warrant to purchase Other Shares of Common Stock in lieu of an increase in the number
of Warrant Shares, the terms of which shall be identical to those of this Warrant, except that such warrant shall be exercisable
into the number of shares of Other Shares of Common Stock that would have been payable to the Holder pursuant to the Distribution
had the Holder exercised this Warrant immediately prior to such record date and with an aggregate exercise price equal to the
product of the amount by which the exercise price of this Warrant was decreased with respect to the Distribution pursuant to the
terms of the immediately preceding clause (i) and the number of Warrant Shares calculated in accordance with the first part of
this clause (ii).

 

(c)    Other
Events. If any event occurs of the type contemplated by the provisions of this Section 2(a) or (b) but not expressly provided
for by such provisions (including without limitation the granting, on a pro rata basis to the holders of the Common Stock, of
stock-appreciation rights, phantom stock units or other shareholder rights with equity features), then the Company’s Board
of Directors will make an appropriate adjustment in the Exercise Price and the number of Warrant Shares so as to protect the rights
of the Holder. For the avoidance of doubt, the parties agree this Section 2(c) shall not apply to (i) the issuance of Common Stock
upon the exercise of options or warrants not granted to the shareholders of the Company as a whole, or (ii) the issuance of Common
Stock, stock options, stock-appreciation rights, restricted stock units, or other forms of equity or equity-linked compensation
under the Company’s equity incentive or purchase plans duly adopted by a majority of the non-employee members of the Board
of Directors of the Company or a committee of non-employee directors established for such purpose.

 

(d)    Weighted-Average
Adjustment to Exercise Price. If the Company, at any time while this Warrant is outstanding, shall issue any Common Stock
or Common Stock Equivalents entitling any person to acquire shares of Common Stock, at an effective price per share less than
the then-current Exercise Price, as adjusted hereunder (any such issuance, other than an issuance of Common Stock or Common Stock
Equivalents in respect of an Exempt Issuance, being referred to as a “Dilutive Issuance”), then the Exercise
Price shall be adjusted in accordance with the following formula:

 

AEP
= EP * [OS + ((DIS * DIP)/EP)] 

 (OS
+ DIS)

 

For
purposes of the foregoing formula:

 

	 	AEP	=	Adjusted
    Exercise Price
	 	 	 	 
	 	EP	=	Exercise
    Price (as in effect immediately prior to adjustment)

 

    5

     

    

 

	 	OS	=	Total number
    of shares of Common Stock and Common Stock Equivalents outstanding immediately prior to the Dilutive (excluding, however,
    Common Stock and Common Stock Equivalents outstanding on account of Exempt Issuances)
	 	 	 	 
	 	DIS	=	Total
    number of shares of Common Stock and Common Stock Equivalents issued in the Dilutive Issuance
	 	 	 	 
	 	DIP	=	The per-share
    price at which Common Stock or Common Stock Equivalents were issued in the Dilutive Issuance

 

Any
such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued; provided, however, that (i) if
an adjustment is made on account of a Dilutive Issuance of Common Stock Equivalents, then the subsequent issuance of actual Common
Stock upon conversion or exercise of such Common Stock Equivalents will not result in a second adjustment, and (ii) notwithstanding
anything in this Warrant to the contrary, no adjustments shall be made under this Section 2(d) in respect of an Exempt Issuance.
The Company shall notify the Holder in writing, no later than the third Trading Day following any Dilutive Issuance (other than
an Exempt Issuance), indicating therein the applicable per-share price at which Common Stock or Common Stock Equivalents were
issued.

 

3.       FUNDAMENTAL
TRANSACTIONS. If, at any time while this Warrant is outstanding, (i) the Company effects any merger of the Company with or
into another entity and the Company is not the surviving entity, (ii) the Company effects any sale of all or substantially all
of its assets in one or a series of related transactions, (iii) any tender offer or exchange offer (whether by the Company or
by another individual or entity, and approved by the Company) is completed pursuant to which holders of Common Stock are permitted
to tender or exchange their shares of Common Stock for other securities, cash or property or (iv) the Company effects any reclassification
of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged
for other securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered
by Section 2(a) above) (in any such case, a “Fundamental Transaction”), then, upon any subsequent exercise
of this Warrant, the Holder shall have the right to receive the number of shares of Common Stock of the successor or acquiring
corporation or of the Company and any additional consideration (the “Alternate Consideration”) receivable upon
or as a result of such reorganization, reclassification, merger, consolidation or disposition of assets by a holder of the number
of shares of Common Stock for which this Warrant is exercisable immediately prior to such event (disregarding any limitation on
exercise contained herein solely for the purpose of such determination). For purposes of any such exercise, the determination
of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate
Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion
the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components
of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon
any exercise of this Warrant following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions,
any successor to the Company or surviving entity in such Fundamental Transaction shall issue to the Holder a new warrant consistent
with the foregoing provisions and evidencing the Holder’s right to exercise such warrant into Alternate Consideration.

 

    6

     

    

 

4.       NON-CIRCUMVENTION.
The Company covenants and agrees that the Company will not, by amendment of its articles of incorporation, bylaws or through
any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities,
or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will
at all times in good faith carry out all the provisions of this Warrant and take all action as may be required to protect the
rights of the Holder. Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of any
shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, (ii) shall take all
such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable
shares of Common Stock upon the exercise of this Warrant, and (iii) shall, so long as this Warrant is outstanding, have authorized
and reserved, free from preemptive rights, a sufficient number of shares of Common Stock to provide for the exercise of the rights
represented by this Warrant (without regard to any limitations on exercise).

 

5.       WARRANT
HOLDER NOT DEEMED A SHAREHOLDER. Except as otherwise specifically
provided herein, this Warrant, in and of itself, shall not entitle the Holder to any voting rights or other rights as a shareholder
of the Company. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to
purchase any securities (upon exercise of this Warrant or otherwise) or as a shareholder of the Company, whether such liabilities
are asserted by the Company or by creditors of the Company.

 

6.       REISSUANCE
OF WARRANTS.

 

(a)Lost,
Stolen or Mutilated Warrant. If this Warrant is lost, stolen, mutilated or destroyed, the Company will, on such terms as to
indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof),
issue a new Warrant of like denomination and tenor as this Warrant so lost, stolen, mutilated or destroyed.

 

(b)Issuance
of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant
shall be of like tenor with this Warrant, and shall have an issuance date, as indicated on the face of such new Warrant which
is the same as the Issuance Date.

 

7.       TRANSFER.

 

(a)Notice
of Transfer. The Holder, by acceptance hereof, agrees to give written notice to the Company before transferring this Warrant
or transferring any Warrant Shares of such Holder’s intention to do so, describing briefly the manner of any proposed transfer.
Promptly upon receiving such written notice, the Company shall present copies thereof to the Company’s counsel. If the proposed
transfer may be effected without registration or qualification (under any federal or state securities laws), the Company, as promptly
as practicable, shall notify the Holder thereof, whereupon the Holder shall be entitled to transfer this Warrant or to dispose
of Warrant Shares received upon the previous exercise of this Warrant, all in accordance with the terms of the notice delivered
by the Holder to the Company; provided, however, that an appropriate legend may be endorsed on this Warrant or the certificates
for such Warrant Shares respecting restrictions upon transfer thereof necessary or advisable in the opinion of counsel and satisfactory
to the Company to prevent further transfers which would be in violation of Section 5 of the Securities Act of 1933 and applicable
state securities laws; and provided further that the prospective transferee or purchaser shall execute an Assignment of Warrant
in substantially the form attached hereto as Exhibit B and such other documents and make such representations, warranties,
and agreements as may be required solely to comply with the exemptions relied upon by the Company for the transfer or disposition
of the Warrant or Warrant Shares.

 

    7

     

    

 

(b)If
the proposed transfer or disposition of this Warrant or such Warrant Shares described in the written notice given pursuant to
this Section 7 may not be effected without registration or qualification of this Warrant or such Warrant Shares, the Holder will
limit its activities in respect to such transfer or disposition as are permitted by law.

 

8.      NOTICES.
Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall be given in
accordance with the notice provisions contained in the Note. The Company shall provide the Holder with prompt written notice (i)
immediately upon any adjustment of the Exercise Price, setting forth in reasonable detail, and certifying, the calculation of
such adjustment and (ii) at least 20 days prior to the date on which the Company closes its books or takes a record (A) with respect
to any dividend or distribution upon the shares of Common Stock, (B) with respect to any grants, issuances or sales of any stock
or other securities directly or indirectly convertible into or exercisable or exchangeable for shares of Common Stock or other
property, pro rata to the holders of shares of Common Stock or (C) for determining rights to vote with respect to any Fundamental
Transaction, dissolution or liquidation, provided in each case that such information shall be made known to the public prior to
or in conjunction with such notice being provided to the Holder.

 

9.       AMENDMENT
AND WAIVER. The terms of this Warrant may be amended or waived (either generally or in a particular instance and either retroactively
or prospectively) only with the written consent of the Company and the Holder.

 

10.     GOVERNING
LAW. This Warrant and all rights, obligations and liabilities hereunder shall be governed by, and construed in accordance
with, the internal laws of the State of New York, without giving effect to the conflicts-of-law principles thereof.

 

11.     DISPUTE
RESOLUTION. In the case of a dispute as to the determination of the Exercise Price, the Closing Sale Price, or the arithmetic
calculation of the Warrant Shares, the Company or the Holder (as the case may be) shall submit the disputed determinations or
arithmetic calculations via facsimile (a) within two business days after receipt of the applicable notice giving rise to such
dispute to the Company or the Holder, as the case may be, or (b) if no notice gave rise to such dispute, at any time after the
Holder learned of the circumstances giving rise to such dispute. If the Holder and the Company are unable to agree upon such determination
or calculation of the Exercise Price, Closing Sale Price or the Warrant Shares within three business days of such disputed determination
or arithmetic calculation being submitted to the Company or the Holder, as the case may be, then the Company shall, within two
business days thereafter submit via facsimile (x) the disputed determination of the Exercise Price or Closing Sale Price to an
independent, reputable investment bank selected by the Company and approved by
the Holder or (y) the disputed arithmetic calculation of the Warrant Shares to the Company’s independent, outside accountant.
The Company shall cause at its expense the investment bank or the accountant, as the case may be, to perform the determinations
or calculations and notify the Company and the Holder of the results no later than ten business days from the time it receives
the disputed determinations or calculations. Such investment bank’s or accountant’s determination or calculation,
as the case may be, shall be binding upon all parties absent manifest error.

 

    8

     

    

 

12.   ACCEPTANCE.
Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained
herein.

 

13.    CERTAIN
DEFINITIONS. For purposes of this Warrant, the following terms shall have the following meanings:

 

(a)“Bloomberg”
means Bloomberg Financial Markets.

 

(b)“Closing
Sale Price” means, for any security as of any date, (i) the last closing trade price for such security on the Principal
Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate
the closing trade price, then the last trade price of such security prior to 4:00 p.m., New York time, as reported by Bloomberg,
or (ii) if the foregoing does not apply, the last trade price of such security in the over-the-counter market for such security
as reported by Bloomberg, or (iii) if no last trade price is reported for such security by Bloomberg, the average of the bid and
ask prices of any market makers for such security as reported by the OTC Markets. If the Closing Sale Price cannot be calculated
for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall
be the fair market value as mutually determined by the Company and the Holder. All such determinations to be appropriately adjusted
for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.

 

(c)“Common
Stock” means (i) the Company’s common stock, par value $0.01 per share, and (ii) any share capital into which
such common stock shall have been changed or any share capital resulting from a reclassification of such common stock.

 

(d)“Common
Stock Equivalents” means any securities of the Company that would entitle the holder thereof to acquire at any time
Common Stock, including without limitation any debt, preferred stock, rights, options, warrants or other instrument that is at
any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

 

(e)“Exempt
Issuance” means the issuance of (i) shares of Common Stock or options to employees, officers, directors or unaffiliated
consultants of the Company pursuant to any stock or option plan duly adopted by a majority of the non-employee members of the
Board of Directors of the Company or a majority of the members of a committee of non-employee directors established for such purpose,
(ii) any securities upon the exercise or conversion of any securities issued pursuant to the Securities Purchase Agreement or
agreements in substantially similar form pursuant to which Notes and Warrants were or are sold, (iii) any Common Stock upon the
exercise or conversion of securities that are issued and outstanding as of the date of the Securities Purchase Agreement, (iv)
securities issued pursuant to or in connection with acquisitions or strategic transactions approved by a majority of the disinterested
directors of the Company, (v) shares of Common Stock issued or issuable in connection with regularly scheduled dividend payments
on the Company’s Series A Preferred Stock, and (vi) shares of Common Stock issued pursuant to any loan or leasing arrangement,
real property leasing

arrangement,
or debt financing from a bank approved by the Board of Directors of the Company.

 

    9

     

    

 

(f)     “Principal
Market” means the primary national securities exchange on which the Common Stock is then traded.

 

(g)    “SEC”
means the U.S. Securities and Exchange Commission.

 

(h)    “Trading
Day” means (i) any day on which the Common Stock is listed or quoted and traded on its Principal Market, (ii) if the
Common Stock is not then listed or quoted and traded on any national securities exchange, then a day on which trading occurs on
any over-the-counter markets, or (iii) if trading does not occur on the over-the-counter markets, any business day.

 

(i)     “Weighted
Average Price” means, for any security as of any date, (i) the dollar-volume weighted-average price for such security
on the Principal Market during the period beginning at 9:30 a.m., New York City time, and ending at 4:00 p.m., New York City time,
as reported by Bloomberg or (ii) if the foregoing does not apply, the dollar-volume weighted-average price of such security in
the over-the-counter market for such security during the period beginning at 9:30 a.m., New York City time, and ending at 4:00
p.m., New York City time, as reported by Bloomberg, or (iii) if no dollar-volume weighted-average price is reported for such security
by Bloomberg for such hours, the average of the highest closing bid price and the lowest closing ask price of any of the market
makers for such security as reported in OTC Markets. If the Weighted Average Price cannot be calculated for such security on such
date on any of the foregoing bases, the Weighted Average Price of such security on such date shall be the fair market value as
mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value
of such security, then such dispute shall be resolved pursuant to Section 12 with the term “Weighted Average Price”
being substituted for the term “Exercise Price.” All such determinations shall be appropriately adjusted for any share
dividend, share split or other similar transaction during such period.

 

*
* * * * * *

 

    10

     

    

 

IN
WITNESS WHEREOF,
the Company has caused this Warrant to Purchase Common Stock to be duly executed as of the date indicated above. 

 

	 	CREATIVE
    REALITIES, INC.
	 	 
	 	/s/
    JOHN WALPUCK
	 	JOHN
                                         WALPUCK

	 	Chief
                                         Financial Officer 

  

     

     

    

 

EXHIBIT
A

 

FORM
OF

EXERCISE
NOTICE

 

(To
be executed by the registered holder to exercise this Warrant to Purchase Common Stock)

 

THE
UNDERSIGNED holder hereby exercises the right
to purchase____________________________of the shares of Common Stock (“Warrant Shares”) of Creative Realities,
Inc., a Minnesota corporation (the “Company”), evidenced by the attached copy of the Warrant to Purchase Common Stock
(the “Warrant”). Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth
in the Warrant.

 

		1.	Form
                                         of Exercise Price.
                                         The Holder intends that payment of the Exercise Price shall be made as (check one):

 

☐     a
cash exercise with respect to________________________Warrant Shares; and/or

 

☐     a
“Cashless Exercise” with respect to_______________________Warrant Shares.

 

		2.	Payment
                                                                                                                                                                                                                                                                                            of Exercise Price. In the event that the holder has elected to exercise some or all of the Warrant Shares to be issued
                                                                                                                                                                                                                                                                                            pursuant hereto, the holder shall pay the Aggregate Exercise Price
                                                                                                                                                                                                                                                                                            in the sum of $_______________________________ to the Company in accordance with the terms of the Warrant.

 

		3.	Delivery
                                         of Warrant Shares.
                                         The Company shall deliver to the holder _______________Warrant Shares in accordance with the terms of
                                         the Warrant.

 

Date:                                          

 

	 	 
	 	(Print
    Name of Registered Holder)

 

	 	By:
    	 
	 	Name:	 
	 	Title:	 

 

     

     

    

 

EXHIBIT
B

 

FORM
OF

ASSIGNMENT
OF WARRANT

 

(To
be signed only upon authorized transfer of the Warrant)

 

FOR VALUE
RECEIVED, the undersigned hereby sells, assigns, and
transfers unto _______________________ the right to purchase_____________________ shares of common stock of Creative
Realities, Inc., to which the within Warrant to Purchase Common Stock relates and appoints ______________________ , as
attorney-in-fact, to transfer said right on the books of Creative Realities, Inc. with full power of substitution and
re-substitution in the premises. By accepting such transfer, the transferee has agreed to be bound in all respects by the
terms and conditions of the within Warrant.

 

Dated: _________________

 

	 	 
	 	(Signature)
    *
	 	 
	 	 
	 	(Name)
	 	 
	 	 
	 	(Address)
	 	 
	 	 
	 	(Social
    Security or Tax Ident. No.)

 

*
The signature on this Assignment of Warrant must correspond to the name as written upon the face of the Warrant to Purchase Common
Stock in every particular without alteration or enlargement or any change whatsoever. When signing on behalf of a corporation,
partnership, trust or other entity, please indicate your position(s) and title(s) with such entity.Exhibit 10.1

 

 

 

October 18, 2014

 

 

Michael D. Becker

1478 Greenmeadows Road

Yardley, PA 19067

 

Dear Mr. Becker,

 

On behalf of Relmada Therapeutics,
Inc: (the "Company"), I am pleased to offer you the position of Senior Vice President of Finance and Corporate Development.
Speaking for myself, as well as the other members of the management team, we are all impressed with your credentials and look forward
to your future success in this position. The terms of your employment are set herein ("Employment Letter").

 

1. Position. The terms of your new position
with the Company are as set forth below:

 

(a) You shall serve as
Senior Vice President of Finance and Corporate Development of the Company with such responsibilities duties and authority as are
assigned to you by the Office of the CEO (that comprises the Chief Executive Officer and a Board Designee). You shall report directly
to the Office to the CEO and shall perform your duties for the Company at the Company’s offices except for travel that may
be necessary or appropriate in connection with the performance of your duties hereunder. The office is located in New York City.

 

(b) Employee shall
faithfully devote his full business/working time, attention and energy to the business and affairs of the Company and the
performance of his duties, which may be modified periodically by the Office of the CEO and to use his best efforts to perform
such responsibilities faithfully and efficiently. Without limiting the generality of the foregoing paragraph, the employee
may join professional associations and otherwise be involved with any other business activities, to the extent that, in the
reasonable judgment of the Office of the CEO, such other business pursuits and activities do not (i) interfere in any
material respect with Employee's ability to discharge Employee's duties and responsibilities to the Company, whether or not
such activity is pursued for gain, profit or other pecuniary advantage, or (ii) violate the Conflicts provision of Employee's
Non-Disclosure Agreement.

 

2. Start Date.
Subject to fulfillment of any conditions imposed by this letter agreement, you will commence this new position with the Company
on November 1, 2014 (“Start Date”). The Company has the right to withdraw the offer contemplated
by this Letter Agreement if you are unable to fulfill the Start Date requirement.

 

    1

     

    

 

 

3. Proof of Right to Work. For purposes
of federal immigration law, you will be required to provide to the Company documentary evidence of your identity and eligibility
for employment in the United States. Such documentation must be provided to us within three (3) business days of your date of hire,
or our employment relationship with you may be terminated.

 

4. Compensation.

 

(a) Base
Salary. You will be paid an annual base salary of one hundred and seventy five thousand dollars ($175,000), which will be
paid in accordance with the Company's regular payroll practices. Your base salary shall be reviewed at 90 days from the Start
Date by management of the Company, and at the discretion of the Company, may be increased to two hundred thousand dollars
($200,000). The proposed increase in base salary shall be payable at the first regular pay period after the 90 day period
from your Start Date.

 

(b) Performance Cash
Bonus. You shall be entitled to participate in a bonus program, which shall be established by the Board pursuant to which the
Board shall award bonuses to you, based upon the achievement of written individual and corporate objectives such as the
Office of the CEO or Board shall determine. Upon the attainment of such performance objectives, in addition to your base
salary, you shall be entitled to a cash bonus in an amount to be determined by the Board with a target of twenty-five percent
(25%) of your base salary. Any such performance bonus shall be due and payable within ninety (90) days after the end of the
calendar year to which it relates.

 

(c) Equity Grant. The
Board has agreed to grant to you options to purchase common shares and restricted common stock of the Company (the
“Initial Grant") under the Company’s current Stock Option and Equity Incentive Plan. The initial Grant will .consist
of (i) an option grant to purchase up to one hundred fifty thousand (150,000) common shares (the "Options”)
and (ii) one hundred thousand (100,000) shares of restricted common stock of the
Company (the “Restricted Stock”). The terms of Options and Restricted Stock shall be governed
under-the Company's Stock Option Plan. The Initial Grant is subject to final approval by the Board.

 

(i) Stock exercise price
for Options. The Options of the Initial Grant will have an exercise price equal to the closing
price of the Company’s common stock on the Start Date, as quoted on the OTCBB under the symbol RLMD, which is equal to the
fair market-value of the Company’s common stock on the date of the grant. The- stock options of the initial
Grant Shall have a term of 10 years starting from the first day of your employment with the Company (the "Grant Date").
The stock Options shall vest in compliance with Section 4(c)(ii) below.

 

    2

     

    

 

 

 

(ii) Vesting Schedule.
The Options and Restricted Stock of the Initial Grant shall begin to vest on the Grant Date based on the following vesting schedule:
Twenty-five percent (25%) of the stock options and Restricted Stock of the Initial Grant shall vest on the first anniversary of
the Grant Date and the remaining seventy-five percent (75%) of each of the Options and Restricted Stock shall vest in equal quarterly
increments of 6.25% of the initial Option Grant over the following three (3) year period.

 

(d) Withholding of
Taxes. You understand that the services to be rendered hereunder will cause you to recognize taxable income, which is
considered under the Internal Revenue Code of 1986, as amended, and applicable regulations thereunder as compensation income
subject to the withholding of income tax (and Social Security or other employment taxes). You hereby consent to the
withholding of such taxes as are required by the Company.

 

5. Benefits.

 

(a) Benefit Plan –
Health Insurance, Retirement and Stock Option Plan. The Company will provide you with the opportunity to participate in the
standard benefits plans currently available to other similarly situated employees. The Company reserves the right to cancel and/or
change the benefits plans it offers to its employees at any time, subject to applicable law.

 

(b) Vacation; Sick Leave.
You will be entitled to 20 days paid vacation per year, pro-rated for the remainder of this calendar year and pro-rated by the
number of hours worked. Vacation may not be taken before it is accrued. You will be entitled to 5 days paid sick leave per year
pro-rated.

 

(c) Other Benefits.
The Company will provide you with standard business reimbursements (including mileage, supplies, long distance calls), subject
to Company policies and procedures and with appropriate receipts. In addition, you will receive any other statutory benefits required
by law.

 

(d) Reimbursement of Expenses.
You shall be reimbursed for all normal items of travel and entertainment and miscellaneous expenses reasonably incurred by you
on behalf of the Company provided such expenses are documented and submitted in accordance with the reimbursement policies in effect
from time to time.

 

    3

     

    

 

 

 

6. Confidential Information
and Invention Assignment Agreement. Your acceptance of this offer and commencement of employment with the Company is contingent
upon the execution, and delivery to an officer of the Company, of the Company’s Confidential Information and Invention Assignment
Agreement, a copy of which is enclosed for your review and execution (the “Confidentiality Agreement”), prior
to or on your Start Date.

 

7. At-Will Employment
and Termination of Employment.

 

(a) Your.
employment with the Company will be on an "at will" basis meaning that either you or the Company may terminate
your employment at any time for any reason or no reason, upon written notification to the other party, without further
obligation or liability, except that upon termination of your employment by the Company, other than for cause, you will be paid
a severance pay in compliance with Section 7(b) and (c) below.

 

(b)
Upon Termination for cause you shall be immediately paid all accrued salary, bonuses, incentive compensation to the extent
earned, vested deferred compensation pension plan and profit sharing plan benefits, which will he paid in accordance with the applicable
plan, and accrued vacation pay, all to the date of termination. In the event of termination other than for cause, you will be entitled
to severance equal to three months of base salary and health benefits. For the avoidance of doubt, if you are terminated for cause,
you shall not be entitled to any severance payments or health benefits.

 

(c) Upon any termination
other than for cause you will immediately be paid all accrued salary, bonuses and incentive compensation to the extent earned,
vested deferred compensation pension plan and profit sharing plan benefits, which will be paid in accordance with the applicable
plan, and accrued vacation pay, all to the date of termination. Additionally, notwithstanding anything contained herein or any
applicable plan to the contrary, all unvested, unexercisable and stock options and stock grants, if applicable, for which you are
eligible pursuant to the terms hereof shall automatically be cancelled on at the termination date of employment. You will have
90 days from the date of termination to exercise your vested options.

 

8. Non-Solicitation.
You agree that during the entire term of your employment with the Company, and for a period of 24 months following the cessation
of employment with the Company for any reason or no reason, you shall not directly or indirectly solicit, induce, recruit or encourage
any of the Company’s employees or consultants to terminate their relationship with the Company, or attempt any of the foregoing,
either for yourself or any other person or entity. For a period of 24 months following cessation of employment with the Company
for any reason or no reason, you shall not attempt to negatively influence any of the Company’s clients or customers from
purchasing Company products or services or to solicit or influence or attempt to influence any client, customer or other person
either directly or indirectly, to direct his or its purchase of products and/or services to any person, firm, corporation, institution
or other entity in competition with the business of the Company.

 

    4

     

    

 

 

 

9. Arbitration.
This Agreement is to be governed by and construed in accordance with the laws of the State of New York applicable to contracts
entered into and wholly to be performed within the State of New York by New York residents. Any controversy or claim arising out
of or relating to this Agreement, or breach of this Agreement (except for any controversy or claim with respect to Section 6 or
Section 8, which may be submitted, at the option of the Company, to any court of competent jurisdiction located within New York,
New York) is to be settled by arbitration in New York, NY in accordance with the Commercial Arbitration Rules of the American Arbitration
Association, and judgment on the award rendered by the arbitrators may be entered in any court having jurisdiction. There must
be three arbitrators, one to be chosen directly by each party at will, and the third arbitrator to be selected by the two arbitrators
so chosen. Each party will pay the fees of the arbitrator he or she selects and his or her own attorneys, and the expenses of his
or her witnesses and all other expenses connected with presenting his or her case. Other costs of the arbitration, including the
cost of any record or transcripts of the arbitration, administrative fees, the fee of the third arbitrator, and all other fees
and costs, will be borne equally by the parties. Notwithstanding the foregoing, the parties may apply to any court of competent
jurisdiction for preliminary or interim equitable relief, or to compel arbitration in accordance with this paragraph, without breach
of this arbitration provision.

 

10. Miscellaneous.
This Employment Letter, together with the Confidentiality Agreement, sets forth the terms of your employment with the Company and
supersedes any prior representations or agreements, whether written or oral. This Employment Letter may not be modified or amended
except by a written agreement, signed by the Company and by you. Whenever possible, each provision of this Agreement will be interpreted
in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid,
illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability
will be lessened or reduced to the extent possible or will be severed and will not affect any other provision and this Agreement
will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never
been contained herein. This Agreement will be governed by New York law without reference to rules of conflicts of law. The waiver
of any breach of any provision of this Employment Letter will not operate or be construed as a waiver of any subsequent breach
of the same or other provision of this Employment Letter. This Agreement will be binding on, and inure to the benefit of, the executors,
administrators, heirs, successors, and assigns of the parties; provided, however, that except as expressly provided in this Agreement,
this Agreement may not be assigned either by Company or by Employee. This Agreement may be executed in one or more counterparts,
all of which taken together will constitute one and the same Agreement.

 

    5

     

    

 

 

 

11. Notices.All
notices, requests, demands and other communications called for hereunder shall be in writing and shall be deemed given (i) on the
date of delivery if delivered personally, (ii) one (1) day after being sent by a well established commercial overnight service,
(iii) three (3) days after being mailed by registered or certified mail, return receipt requested, prepaid and addressed to the
parties or their successors at the following addresses, or at such other addresses as the parties may later designate in writing,
(iv) upon confirmation of facsimile transfer, if sent by facsimile or (v) upon confirmation of delivery when directed to the electronic
mail address set forth below, if sent by electronic mail:

 

	 	If to the Company:	 	546 Fifth Avenue, 14th Floor  
		 	 	New York, NY 10036
	 	 	 	Fax No.: 1 888 228 5672
	 	 	 	Email address:  st@relmada.com
	 	 	 	 
	 	If to you:	 	1478 Greenmeadows Road
	 	 	 	Yardley, PA 19067
	 	 	 	Email address: Michael@mdbllc.com

 

 

(Signature page follows)

 

    6

     

    

 

 

 

IN WITNESS WHEREOF, the
parties hereto have executed this Employment Agreement as of the date first written above.

 

	RELMADA THERAPEUTICS, INC.	 	MICHAEL D. BECKER
	 	 	 	 
	By:	/s/ Sergio Traversa	 	/s/ Michael D. Becker
	 	Sergio Traversa, CEO	 	 

  

 

 

7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}]]